Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.

Korinna Karampampa Wenjie Zhang Meena Venkatachalam Francois-Emery Cotté Devender Dhanda

Published in: Journal of medical economics (2023)

Ide-cel was associated with significant survival improvements in terms of both LYs and QALYs in patients with progressive triple-class-exposed RRMM. The ICER for ide-cel was similar to that of other approved and reimbursed RRMM therapies.

Keyphrases

multiple myeloma
end stage renal disease
newly diagnosed
healthcare
ejection fraction
chronic kidney disease
acute myeloid leukemia
multiple sclerosis
palliative care
prognostic factors
peritoneal dialysis
diffuse large b cell lymphoma
quality improvement
hodgkin lymphoma